Megace
(Megestrol Acetate)ApprovedSmall molecule
Bristol-Myers SquibbMegestrol acetate is used to treat loss of appetite and weight loss in patients with AIDS, and to treat certain types of cancer (particularly endometrial and breast cancer). It can help patients regain appetite and gain weight.[2] Megace is currently approved and in use across 29 indications[4].[1]
Megace is one of 586 small molecule programs targeting AIDS. It is currently in Approved.
29
Indications
57
Total Trials
13
Active Trials
585
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 28 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Megace
Bristol-Myers SquibbApproved
Adriamycin
GGynecologic Oncology Group
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Avastin
RochePreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Weight loss10 trials
Show 7 more trials
Endometrial Cancer10 trials
Show 7 more trials
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
Active, not recruiting·—·Phase 2·NCT03671811·44 enrolled
Atypical Endometrial Hyperplasia5 trials
Breast Cancer4 trials
A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer
Completed·—·Phase 2·NCT03306472·198 enrolled
Hyperplasia4 trials
18 more indications
Megestrol Acetate3 trials
Endometrial Carcinoma3 trials
Anorexia2 trials
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.
Unknown status·—·Phase 2·NCT05380479·80 enrolled
Lung Cancer2 trials
Liver Cancer1 trial
Adenocarcinoma1 trial
Randomized1 trial
Endometrioid Carcinoma1 trial
Central precocious puberty1 trial
Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine
Completed·—·Phase 4·NCT03963752·126 enrolled
Combination Therapy1 trial
Chronic Obstructive Pulmonary Disease1 trial
Nausea and vomiting1 trial
A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT07254416·120 enrolled
Malnutrition1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Megace drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Megestrol Acetate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Progesterone Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company